Asian Session
Current Lipid Control for Vascular Protection in Asia

In Asian countries, the numbers of patients with dyslipidemia, obesity, and diabetes mellitus are growing due to the westernized lifestyle, and as the result, the risk of macrovascular event is rapidly increasing. Statin shows a great effect on cardiovascular event reduction, and strict lipid-lowering therapy according to the complications is recommended in the guidelines. Population in Asia will continue to expand, and lipid-lowering therapy with medical agent including statin for the primary and secondary prevention of cardiovascular disease become more important, and concurrently, the cost-benefit performance of medications must be well considered. We will discuss about management of dyslipidemia in Asia, and we believe that this symposium will help us to set the future vision of atherosclerosis prevention.